NuPathe crossed the regulatory finish line with FDA approval of its migraine patch, Zecuity, overcoming the agency's concerns about the battery-powered delivery system that prompted a denial from U.S. regulators in 2011.
Hunkering down ahead of a January 17 PDUFA date for its experimental migraine patch, NuPathe says it will lay off half of its staff as it conserves resources, raises cash and looks for a partner to help commercialize the product in the event of an approval.
The FDA has handed NuPathe a complete response letter detailing demands for new information on its experimental migraine patch, Zelrix (NP101). But even after scrambling to try and reassure investors
Conshohocken, PA-based NuPathe has cuts its IPO price to just $10 a share, the company announced today. NuPathe was hoping to raise between $14 and $16 per share for a total of $75 million. The
Conshohocken, PA-based NuPathe, which is developing a transdermal patch version of the popular migraine treatment Imitrex, has set the terms of its proposed IPO. NuPathe will offer 5 million common
Yet another biotech company has announced plans to file an IPO. Conshohocken, PA-based NuPathe, which is developing a transdermal patch to treat migraines, hopes to raise $86.3 million, according to
NuPathe announced positive results from a key late-stage study of Zelrix, a transdermal patch designed for the treatment of acute migraine. The multi-center trial involved 530 adults. Data from the